Key facts
- Sunbird Bio’s last known valuation is $16.0M (Nov 2022).
- It has raised $27.3M across 1 recorded rounds; the latest was Early Stage VC ($23.2M) in Apr 2023.
- Notable investors include Alumni Ventures, EDBI, ARCH Venture Partners, S32, Polaris Partners — 11 tracked in total.
- Sunbird Bio has filed 1 Form D with the SEC, most recently May 2023 ($23.2M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Sunbird Bio
Funding rounds
1 roundsAbout Sunbird Bio
Developer of a diagnostics platform designed to provide fast and accurate results in molecular diagnostics. The company's platform specializes in the detection of a wide range of diseases, which include infectious diseases, neurodegenerative diseases, and cancer, which can be diagnosed early, enabling physicians to improve lives by providing clarity and accessibility in diagnostic testing to better inform healthcare decisions and outcomes.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2020
- Employees
- 32
- Website
- sunbirdbio.com/
- Ownership
- Privately Held (backing)
Sunbird Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sunbird Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sunbird Bio in its N-PORT filings yet. We sweep new filings monthly.